Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Omnicell, Inc. has received an average broker recommendation of "Moderate Buy", with three analysts suggesting a hold and four issuing buy ratings.
• The company's stock saw a price target adjustment with Piper Sandler lowering their target from $57 to $55 and Wells Fargo increasing their target from $37 to $40.
• Insider selling occurred recently, with EVP Corey J. Manley selling 3,880 shares for $129,010, reducing their ownership by 3.39%.

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $46.7143.

Several analysts have weighed in on the company. Wall Street Zen downgraded Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Piper Sandler lowered their price objective on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Finally, Wells Fargo & Company boosted their price objective on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of the business's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $33.25, for a total value of $129,010.00. Following the completion of the sale, the executive vice president owned 110,653 shares in the company, valued at approximately $3,679,212.25. The trade was a 3.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.52% of the company's stock.

Institutional Trading of Omnicell

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in shares of Omnicell during the second quarter valued at approximately $26,000. GAMMA Investing LLC lifted its stake in Omnicell by 37.1% in the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock worth $50,000 after acquiring an additional 458 shares during the period. Tower Research Capital LLC TRC lifted its stake in Omnicell by 385.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,952 shares of the company's stock worth $146,000 after acquiring an additional 3,932 shares during the period. AlphaQuest LLC lifted its stake in Omnicell by 79.0% in the first quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock worth $224,000 after acquiring an additional 2,824 shares during the period. Finally, New Age Alpha Advisors LLC purchased a new stake in Omnicell in the first quarter worth $233,000. Institutional investors own 97.70% of the company's stock.

Omnicell Stock Down 1.2%

Shares of OMCL opened at $30.34 on Tuesday. The firm has a market cap of $1.39 billion, a P/E ratio of 60.68, a P/E/G ratio of 6.71 and a beta of 0.82. The stock has a 50 day simple moving average of $31.34 and a two-hundred day simple moving average of $30.64. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. Omnicell has a 1 year low of $22.66 and a 1 year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.Omnicell's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.